Abstract
CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) chemotherapy, administered every 21 days (CHOP21), has been for years the standard therapy for advanced diffuse large B-cell lymphoma (DLBCL), with a long-term overall survival rate of about 40%.[1][1] Modifications of the CHOP design
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have